NFE2L2 and cardiovascular disorder: The Nrf2 upregulation by the SFN treatment of cardiomyocytes promotes increased expression and activity of Nrf2-associated antioxidant genes, such as NQO-1, HO-1, and GCL, thus contributing to counteracting pathological processes in cardiovascular diseases [98].